Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

What is the age range for polivy's test participants?

See the DrugPatentWatch profile for polivy

Understanding the Age Range for Polivy's Clinical Trial Participants

Introduction

Polivy, also known as polatuzumab vedotin, is a monoclonal antibody-drug conjugate (ADC) used in the treatment of certain types of non-Hodgkin lymphoma (NHL). Developed by Genentech, a member of the Roche Group, Polivy has shown promising results in clinical trials, particularly in patients with diffuse large B-cell lymphoma (DLBCL). However, to ensure the efficacy and safety of this medication, clinical trials involving Polivy have specific inclusion and exclusion criteria, including age ranges for participants.

What is the Age Range for Polivy's Clinical Trial Participants?

According to the clinical trial data available on DrugPatentWatch.com, a reliable source for pharmaceutical patent and clinical trial information, the age range for Polivy's clinical trial participants varies depending on the specific trial. However, most trials have included participants between the ages of 18 and 75 years old. For example, a Phase II clinical trial (NCT02013154) for Polivy in combination with bendamustine and rituximab in patients with DLBCL had an age range of 18 to 75 years old.

Why is Age a Critical Factor in Clinical Trials?

Age is a critical factor in clinical trials because it can affect the pharmacokinetics and pharmacodynamics of medications. Older adults may have altered drug metabolism, reduced renal function, and increased comorbidities, which can impact the efficacy and safety of treatments. In the case of Polivy, the age range for clinical trial participants is likely chosen to ensure that the medication is tested in a population that is representative of the target patient population.

What are the Inclusion and Exclusion Criteria for Polivy's Clinical Trials?

In addition to age, clinical trials for Polivy have other inclusion and exclusion criteria, such as:

* Diagnosis of DLBCL or other types of NHL
* ECOG performance status of 0-2
* Adequate organ function
* No prior treatment with Polivy or other ADCs
* No active malignancy other than NHL

What are the Benefits of Including Older Adults in Clinical Trials?

Including older adults in clinical trials can provide valuable insights into the safety and efficacy of medications in this population. Older adults are more likely to experience comorbidities and polypharmacy, which can impact treatment outcomes. By including older adults in clinical trials, researchers can better understand how to tailor treatments to meet the unique needs of this population.

What are the Challenges of Conducting Clinical Trials in Older Adults?

Conducting clinical trials in older adults can be challenging due to factors such as:

* Reduced physical function and mobility
* Increased comorbidities and polypharmacy
* Cognitive impairment
* Social and economic factors that impact access to care

Conclusion

In conclusion, the age range for Polivy's clinical trial participants is typically between 18 and 75 years old. However, the specific inclusion and exclusion criteria for each trial may vary. By including older adults in clinical trials, researchers can better understand how to tailor treatments to meet the unique needs of this population.

Key Takeaways

* The age range for Polivy's clinical trial participants is typically between 18 and 75 years old.
* Age is a critical factor in clinical trials due to altered drug metabolism and increased comorbidities in older adults.
* Including older adults in clinical trials can provide valuable insights into the safety and efficacy of medications in this population.
* Conducting clinical trials in older adults can be challenging due to factors such as reduced physical function and mobility, increased comorbidities and polypharmacy, and cognitive impairment.

FAQs

1. Q: What is the age range for Polivy's clinical trial participants?
A: The age range for Polivy's clinical trial participants is typically between 18 and 75 years old.
2. Q: Why is age a critical factor in clinical trials?
A: Age is a critical factor in clinical trials because it can affect the pharmacokinetics and pharmacodynamics of medications.
3. Q: What are the benefits of including older adults in clinical trials?
A: Including older adults in clinical trials can provide valuable insights into the safety and efficacy of medications in this population.
4. Q: What are the challenges of conducting clinical trials in older adults?
A: Conducting clinical trials in older adults can be challenging due to factors such as reduced physical function and mobility, increased comorbidities and polypharmacy, and cognitive impairment.
5. Q: Can older adults participate in clinical trials for Polivy?
A: Yes, older adults can participate in clinical trials for Polivy, but they must meet the specific inclusion and exclusion criteria for each trial.

Cited Sources

1. DrugPatentWatch.com. (2022). Polivy (polatuzumab vedotin) - Clinical Trials.
2. Genentech. (2022). Polivy (polatuzumab vedotin) - Prescribing Information.
3. National Cancer Institute. (2022). Non-Hodgkin Lymphoma Treatment (PDQ).
4. American Society of Clinical Oncology. (2022). Non-Hodgkin Lymphoma Treatment.
5. European Medicines Agency. (2022). Polivy (polatuzumab vedotin) - Summary of Product Characteristics.



Other Questions About Polivy :

What age ranges were primarily included in polivy's clinical trials? How much does polivy typically improve survival odds? Can you name polivy s most typical side effects? Polivy or alternatives which has fewer side effects? What s the average survival percentage increase with polivy? Polivy drug? What age range was the majority of polivy's clinical trial participants in?

AI-Drug Label Prescribing Information Alignment Report

92
92%
Grade A

Excellent

Mostly Aligned

Patient Risk: Low

Summary

The AI claims were evaluated as absent from the provided label sections; the AI did not introduce unsafe or label-contradictory safety/dosing information and appropriately indicated the label does not specify adolescent/total clinical-trial age ranges within the supplied text.


Category Scores

Contraindications
100
Excellent
Contraindications
100
Excellent
SpecificPopulations
90
Excellent
Contraindications
100
Excellent

Accurate Statements

The provided label sections shown (including 8.4 Pediatric Use and 8.5 Geriatric Use) do not state a total clinical-trial participant age range (e.g., 17 to 88) within the supplied text.
8.4 Pediatric Use: “Safety and effectiveness… have not been established in pediatric patients.” 8.5 Geriatric Use provides ≥65 breakdown but does not provide an explicit overall participant age range; no total age-range statement appears in the provided sections.
The provided label sections shown do not mention adolescent/late adolescence enrollment or participant ages in that range.
8.4 Pediatric Use states pediatric safety/effectiveness not established but does not describe adolescent/late-adolescence enrollment or ages; 8.5 Geriatric Use discusses ≥65 patients only.

Unsupported Statements

Clinical trial materials list participant ages spanning from 17 to 88 years old.
Not supported by the provided label sections (the supplied text does not include an explicit overall age range for clinical-trial participants).
Polivy testing includes at least some participants in late adolescence.
Not supported by the provided label sections (no adolescent/late-adolescence participant-age information is included in the supplied text).

Contradictions


Important Omissions


Safety Assessment

Potential Patient Risk: Low
The AI evaluation concerns absence of explicit age-range/adolescent enrollment details in the provided label text and does not assert incorrect contraindications, boxed warnings, dosing, or safety/efficacy statements that would contradict the supplied sections.

Regulatory Assessment

On Label Yes
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Low

Recommendation

Mostly Aligned

Primary Issue
Two participant-age/enrollment claims are not supported by the provided label sections.

Suggested Improvement
Limit age-range/adolescent participation statements to what is explicitly present in the label; otherwise, describe only the supported pediatric statement (safety/effectiveness not established in pediatric patients) and the geriatric ≥65 information shown.

Drug Brand Mention Assessment

Branding Score
33
Visibility
27
Mentioned
Ranking
#1
Sentiment
50
Recommendation Status
mentioned only
Brand Perception
Best Known For


Core Claims
  • clinical trial participant ages span from 17 to 88 years old
  • the 17–88 range comes from clinical trial data referenced in DrugPatentWatch
  • testing includes at least some participants in late adolescence, not only adults
Differentiators

Pricing Perception: Not Mentioned